Table 2 Characteristics of lesions in the training set and the testing set
Training set ( n = 208) | Testing set ( n = 84) | p-valuea | |
|---|---|---|---|
Lymph node metastasis (LNM) | |||
Pelvic LNM | 74(35.58%) | 25(29.76%) | 0.34 |
Middle abdominal LNM | 63(30.29%) | 35(41.67%) | 0.06 |
Upper abdominal LNM | 61(29.33%) | 30(35.71%) | 0.29 |
Distant LNM | 26(12.50%) | 16(19.05%) | 0.15 |
Number of metastatic implants | 6.00(3.00,8.00) | 5.50(3.25,8.00) | 0.14 |
Location of metastatic implants | |||
AR-5 (left lower) | 142(68.27%) | 46(54.76%) | 0.04* |
AR-6 (pelvis) | 173(83.17%) | 75(89.29%) | 0.19 |
AR-7 (right lower) | 131(62.98%) | 47(55.95%) | 0.27 |
AR-4 (left flank) | 88(42.31%) | 35(41.67%) | 0.92 |
AR-0 (central) | 95(45.67%) | 37(44.05%) | 0.80 |
AR-8 (right flank) | 147(70.67%) | 55(65.48%) | 0.38 |
AR-3 (left upper) | 129(62.02%) | 57(67.86%) | 0.42 |
AR-2 (epigastrium) | 87(41.83%) | 41(48.81%) | 0.28 |
AR-1 (right upper) | 141(67.79%) | 61(72.62%) | 0.42 |
Pattern of invasion | 0.74 | ||
0 No invasion | 23(11.06%) | 13(15.48%) | |
1 Nodular type | 42(20.19%) | 18(21.43%) | |
2 Predominantly nodular type | 51(24.52%) | 18(21.43%) | |
3 Predominantly infiltrate type | 52(25.00%) | 17(20.24%) | |
4 Infiltrate type | 40(19.23%) | 18(21.43%) | |